Management of sialorrhoea in motor neuron disease: A survey of current UK practice

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue 7-8, 2013, Pages 521-527

  Hobson, Esther V ^a   McGeachan, Alexander ^a   Al Chalabi, Ammar ^b   Chandran, Siddharthan ^c   Crawley, Francesca ^d   Dick, David ^e   Donaghy, Colette ^f   Ealing, John ^g   Ellis, Cathy M ^b   Gorrie, George ^h   Hanemann, C Oliver ⁱ   Harrower, Timothy ^j   Jung, Agam ^c   Majeed, Tahir ^k   Malaspina, Andrea ^l   Morrison, Karen ^m   Orrell, Richard W ⁿ   Pall, Hardev ^m   Pinto, Ashwin ^o   Talbot, Kevin ^p   Turner, Martin R ^p   Williams, Timothy L ^c   Young, Carolyn A ^q   Shaw, Pamela J ^a   McDermott, Christopher J ^a   more..

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Royal Infi Rmary of Edinburgh ^*  (United Kingdom)

^d WEST SUFFOLK HOSPITAL   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f ROYAL VICTORIA HOSPITAL   (United Kingdom)

^g HOPE HOSPITAL   (United Kingdom)

^h SOUTHERN GENERAL HOSPITAL   (United Kingdom)

ⁱ PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^j Royal Devon and Exeter Foundation Trust Hospital   (United Kingdom)

^k ROYAL PRESTON HOSPITAL   (United Kingdom)

^l QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^m QUEEN ELIZABETH HOSPITAL   (United Kingdom)

ⁿ NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^o SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

more..

Author keywords

Amyotrophic lateral sclerosis; Botulinum toxin; Motor neuron disease; Sialorrhoea

Indexed keywords

AMITRIPTYLINE; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBOCISTEINE; GLYCOPYRRONIUM BROMIDE; ORPHENADRINE; PROPANTHELINE BROMIDE; SCOPOLAMINE;

ARTICLE; DYSPHAGIA; EVIDENCE BASED PRACTICE; FRUIT JUICE; HEALTH PERSONNEL ATTITUDE; HUMAN; HYPERSALIVATION; MOTOR NEURON DISEASE; NEUROLOGIST; PAPAYA; PREVALENCE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM;

ATTITUDE OF HEALTH PERSONNEL; BOTULINUM TOXINS; DATA COLLECTION; DISEASE MANAGEMENT; GREAT BRITAIN; HUMANS; MOTOR NEURON DISEASE; PHYSICIANS; SIALORRHEA;

EID: 84887496547     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.790452     Document Type: Article

References (33)

1. WG, Anderson F, Bromberg M, Gutmann L, Harati Y, Ross M, et al. Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology. Neurology. 2001; 57:500-4.
2. Young CA, Ellis C, Johnson J, Sathasivam S, Pih N. T reatment for sialorrhoea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev. 2011; 5:CD006981.
3. Newall AR, Orser R, Hunt M. T he control of oral secretions in bulbar ALS/MND. J Neurol Sci. 1996; 139 (Suppl):43-4.
4. Oliver D. The quality of care and symptom control: the effects on the terminal phase of ALS/MND. J Neurol Sci. 1996; 139 (Suppl):134-6.
5. Reddihough D, Erasmus CE, Johnson H, McKellar GMW, Jongerius PH. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol. 2010; 17:109-21.
6. Rowland L P, Shneider N A. Amyotrophic lateral sclerosis. N Eng J Med. 2001; 344:1688-700.
7. Peysson S, Vandenberghe N, Philit F, Vial C, Petitjean T, Bouhour F, et al. Factors predicting survival following noninvasive ventilation in amyotrophic lateral sclerosis. Eur Neurol. 2008; 59:164-71.
8. Miller R G, Jackson C E, Kasarskis E J, England J D, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis. Multidisciplinary care, symptom management, and cognitive/behavioural impairment (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009; 73:1227-33.
9. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012; 19:360-75.
10. Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascian à R, et al. Botulinum toxin A versus B in sialorrhoea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord. 2011; 26:313-9.
11. Jackson C E, Gronseth G, Rosenfeld J, Barohn R J, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhoea in ALS patients. Muscle Nerve. 2009; 39:137-43.
12. Rosales RL, Bigalke H, Dressler D. P harmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006; 13 (Suppl 1):2-10.
13. Tan E-K. B otulinum toxin treatment of sialorrhoea: comparing different therapeutic preparations. Eur J Neurol. 2006; 13 (Suppl 1):60-4.
14. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. The Journal of Physiology. 1949; 109:10-24.
15. Andersen P M, Gr ön berg H, Franzen L, Funeg år d U. External radiation of the parotid glands signifi cantly reduces drooling in patients with motor neuron disease with bulbar paresis. J Neurol Sci. 2001; 191:111-4.
16. Guy N, Bourry N, Dallel R, Dual é C, Verrelle P, Lapeyre M, et al. Comparison of radiotherapy types in the treatment of sialorrhoea in amyotrophic lateral sclerosis. J Palliat Med. 2011; 14:391-5.
17. Harriman M, Morrison M, Hay J, Revonta M, Eisen A, Lentle B. Use of radiotherapy for control of sialorrhoea in patients with amyotrophic lateral sclerosis. The Journal of Otolaryngology. 2001; 30:242-5.
18. Neppelberg E, Haugen DF, Thorsen L, Tysnes O-B. Radiotherapy reduces sialorrhoea in amyotrophic lateral sclerosis. Eur J Neurol. 2007; 14:1373-7.
19. Martin TJ, Conley S F. L ong-term effi cacy of intra-oral surgery for sialorrhoea. Otolaryngology-head and neck surgery: offi cial journal of American Academy of Otolaryngology-Head and Neck Surgery. 2007; 137:54-8.
20. Oliveira RS, Resende C, Campos J, Salgado C. S urgical approach to sialorrhoea: a casuistic review and evaluation of grade of satisfaction. Cir Pediatr. 2010; 23:211-4.
21. Stamataki S, Behar P, Brodsky L. S urgical management of drooling: clinical and caregiver satisfaction outcomes. Int J Pediatr Otorhinolaryngol. 2008; 72:1801-5.
22. Blackhall L J. A myotrophic lateral sclerosis and palliative care: where we are, and the road ahead. Muscle Nerve. 2012; 45:311-8.
23. Walshe M, Smith M, Pennington L. I nterventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012; 2:CD008624.
24. Chou K L, Evatt M, Hinson V, Kompoliti K. S ialorrhea in Parkinson's disease: a review. Mov Disord. 2007; 22:2306-13.
25. Perez Lloret S, Pir án Arce G, Rossi M, Caivano Nemet ML, Salsamendi P, Merello M. Validation of a new scale for the evaluation of sialorrhoea in patients with Parkinson's disease. Mov Disord. 2007; 22:107-11.
26. Abdelnour-Mallet M, Tezenas Du Montcel S, Cazzolli PA, Assouline A, Pointon C, Leveque N, et al. Validation of robust tools to measure sialorrhoea in amyotrophic lateral sclerosis: a study in a large French cohort. Amyotroph Lateral Scler. 2013; 14:302-307.
27. H opcutt B, Alnufoury H. S ialorrhoea treatment algorithm for MND. Available from: www.mndassociation.org/forprofessionals/sharing-good-practice/ care-pathway-andclinical-guideline-examples.htm.
28. Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, et al. Amyotrophic lateral sclerosis in south-east England: a population based study. The South-East England Register for Amyotrophic Lateral Sclerosis (SEALS registry). Neuroepidemiology. 2007; 29:44-8.
29. PatientsLikeMe. What we have learned from patients with ALS (amyotropic lateral sclerosis) who report excess saliva. 2012; Available from: www.PatientsLikeMe.com.
30. Meijer J-WG, van Kuijk AA, Geurts ACH, Schelhaas HJ, Zwarts MJ. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2008; 87:321-4.
31. Tan E-K, Lo YL, Seah A, Auchus A P. R ecurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001; 190:95-7.
32. Haverkamp LJ, Appel V, Appel SH. N atural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995; 118:707-19.
33. O'Neill CL, Williams T L, Peel ET, McDermott CJ, Shaw PJ, Gibson GJ, et al. Non-invasive ventilation in motor neuron disease: an update of current UK practice. J Neurol Neurosurg Psychiatry. 2012; 83:371-6.